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Abstract
Aims: Obesity is a primary contributor to acquired insulin resistance leading to the development of type 2 diabetes and
cardiovascular alterations. The carnitine derivate, propionyl-L-carnitine (PLC), plays a key role in energy control. Our aim was
to evaluate metabolic and cardiovascular effects of PLC in diet-induced obese mice.
Methods: C57BL/6 mice were fed a high-fat diet for 9 weeks and then divided into two groups, receiving either free-
(vehicle-HF) or PLC-supplemented water (200 mg/kg/day) during 4 additional weeks. Standard diet-fed animals were used
as lean controls (vehicle-ST). Body weight and food intake were monitored. Glucose and insulin tolerance tests were
assessed, as well as the HOMAIR, the serum lipid profile, the hepatic and muscular mitochondrial activity and the tissue nitric
oxide (NO) liberation. Systolic blood pressure, cardiac and endothelial functions were also evaluated.
Results: Vehicle-HF displayed a greater increase of body weight compared to vehicle-ST that was completely reversed by
PLC treatment without affecting food intake. PLC improved the insulin-resistant state and reversed the increased total
cholesterol but not the increase in free fatty acid, triglyceride and HDL/LDL ratio induced by high-fat diet. Vehicle-HF
exhibited a reduced cardiac output/body weight ratio, endothelial dysfunction and tissue decrease of NO production, all of
them being improved by PLC treatment. Finally, the decrease of hepatic mitochondrial activity by high-fat diet was reversed
by PLC.
Conclusions: Oral administration of PLC improves the insulin-resistant state developed by obese animals and decreases the
cardiovascular risk associated to this metabolic alteration probably via correction of mitochondrial function.
Citation: Mingorance C, Duluc L, Chalopin M, Simard G, Ducluzeau P-H, et al. (2012) Propionyl-L-carnitine Corrects Metabolic and Cardiovascular Alterations in
Diet-Induced Obese Mice and Improves Liver Respiratory Chain Activity. PLoS ONE 7(3): e34268. doi:10.1371/journal.pone.0034268
Editor: Silvana Gaetani, Sapienza University of Rome, Italy
Received July 19, 2011; Accepted February 24, 2012; Published March 23, 2012
Copyright:  2012 Mingorance et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was supported by the following: to CM: Postgraduate National Program of FPU fellowship from the Spanish Ministry of Education and
Science (www.educacion.es); to LD: recipient from INSERM and the Ministry of Education and Research (www.inserm.fr,www.enseignementsup-recherche.gouv.fr).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ramaroson.andriantsitohaina@univ-angers.fr
Introduction
Obesity is a fast growing problem that is reaching epidemic
proportions worldwide, and is associated with an increased risk of
premature death [1]. Individuals with a central deposition of
adipose tissue display elevated cardiovascular morbidity and
mortality, including stroke, congestive heart failure, myocardial
infarction and cardiovascular death, and this is independent of the
association between obesity and other cardiovascular risk factors
[2,3]. Obesity, in particular abdominal obesity, was pointed out as
a primary contributor to acquired insulin resistance, as increasing
adiposity is correlated with impaired insulin action, and partici-
pated to an increased occurrence of type 2 diabetes.
Propionyl-L-carnitine (PLC) is a short chain fatty acid esterified
to carnitine that is rapidly transported into cells, in particular to
the mitochondria, where it is transformed into free carnitine and
propionyl coenzyme A [4,5]. The latter is converted into succinyl
coenzyme A and finally to succinate, which is involved in the citric
acid cycle. Through this mechanism, PLC supplies energy to
ischaemic tissues [4,6]. L-carnitine plays an important role in the
transport of long-chain fatty acids into the mitochondrial matrix,
since it serves as an essential substrate for the enzyme which
catalyses the initial step of b-oxidation, carnitine palmitoyltrans-
ferase 1. Thus, both carnitine and PLC play significant roles in
fatty acid oxidation and energy expenditure. Additionally, both
compounds exert protective effects on vascular endothelium [7–9].
Acute L-carnitine administration has demonstrated some
beneficial effects on glucose disposal of patients with diabetes
(for review see: [10]). However, long-term administration, whole-
body effects, as well as the mechanisms leading to such effects, has
been poorly evaluated. We have recently evaluated the preventive
effect of PLC on obese Zucker rats as an animal model of obesity
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34268and insulin resistance [11]. In this previous study, PLC decreases
body weight gain, food intake, adiposity, insulin serum concen-
tration and triglyceride liver content and improved insulin
resistance [11]. However, preventive but not PLC treatment
effect, once obesity has been established, has been evaluated in our
former study. Besides, the excess of plasma non esterified fatty acid
(NEFA) associated with obesity has been extensively pointed out as
the main cause leading to the insulin-resistant state and
development cardiovascular complications secondary to chronic
overweight [12,13]. Thus, an experimental model that represents
the progressive development of insulin resistance in obesity is the
mouse fed with high-fat (HF) diet. Therefore, the aim of the
present study was to evaluate the effects of oral administration of
PLC on mice in which obesity has been already established using
the HF diet in order to test the hypothesis that PLC might be used
as a treatment strategy.
Materials and Methods
Animals and protocol design
Six week old C57BL/6 mice (Janvier, Paris, France) were fed
with a HF diet 242% kcal from fat, 15.2% kcal from proteins and
42.7% kcal from carbohydrates- (TD. 88137, Harlan, Barcelona,
Spain) for 9 weeks. Once diet-induced obesity (DIO) was reached,
animals were divided into two groups of n=10, receiving either
water (vehicle-HF) or PLC-supplemented drinking water
(200 mg kg
21 day
21, PLC-HF) during 4 weeks. Ten animals
receiving a standard diet and water were used as a lean group
(vehicle-ST). Body weight and food intake were controlled every
three days and water intake daily monitored. The concentration of
PLC contained in the drinking water was weekly readjusted, taking
into account both the average daily water intake and the weekly
body weight. The selected dose of PLC has been previously
reported to improve endothelial function in spontaneously
hypertensive rats [7–9] and to prevent obesity development and
insulin resistance in fatty Zucker rats [10]. Additionally, this dose
assures the increase of L-carnitine tissue levels since a similar dose
of PLC (180 mg/kg/day) administered in the drinking water
during two weeks led to an increase in the cardiac total carnitine
content [14]. At the end of treatment period, animals were
anesthetized with isoflurane and blood was harvested by
intracardiac puncture. Lungs, spleen, kidneys, pancreas, heart,
liver and epididymal, abdominal, mesenteric and subcutaneous
fats were isolated and weighted.
The protocol for animal handling and experimentation of this
investigation was in accordance with the European Union
European Community guidelines for the ethical treatment of
animals (European Economic Community Directive of 1986; 86/
609/EEC) and was approved by the Ethical Committee for
Animal Research of Seville University (Approval ID: 20090527).
Glucose tolerance and insulin tolerance tests
After four weeks receiving vehicle or PLC, intraperitoneal
glucose tolerance test and insulin tolerance test were performed.
The glucose tolerance test was performed by injection of glucose
(2 g/kg body weight) to mice previously starved for 12 h. Blood
samples were collected from the tail vein just before and at 30, 60,
90, and 120 min after the administration of glucose. Plasma
glucose concentration was determined using a blood glucose
commercial monitoring meter (Optimun Xceed, Abbot, Rungis,
France) and reactive strips (Optium reactives strips, Abbot,
Rungis, France).
The insulin tolerance test was performed by injection of insulin
(0.8 UI/kg body weight, Humulina Regular, Lilly, Madrid, Spain)
to mice previously starved for 4 h. Then, plasma glucose
concentration was determined before and at after 30, 60, 90 and
120 min after the administration of insulin.
Biochemical profile
Serum samples were obtained from blood by centrifugation for
15 min at 950 g and room temperature. Fasting glucose, insulin
and NEFA were measured using commercial kits (SpinReact,
Gerona, Spain; Millipore, Billerica, MA and WakoChemicals,
Neuss, Germany, respectively). Triglycerides, total cholesterol, low
density lipoprotein (LDL) cholesterol and high density lipoprotein
(HDL) cholesterol were measured with respective enzymatic kits
from Roche Diagnostics. The homeostasis model assessment to
quantify insulin resistance (HOMAIR) was calculated as previously
described [15].
Free carnitine and acyl-carnitines analysis
Free carnitine and acylcarnitines analysis was performed by
derivatization to butyl esters and flow injection electrospray
ionization tandem mass spectrometry (ESI-MS/MS). Carnitine
and its acyl esters were detected by looking for the precursor ions
of m/z=85 using an applied Biossytems Sciex (API 3000).
Quantitative analysis was achieved by comparing the signal
intensity of an analyst against the corresponding internal standard.
Long chain fatty acids refer to the sum of C10 to C18.
Systolic blood pressure
Blood pressure was measured using the non invasive tail-cuff
technique three times a week. Each mouse was trained to the tail-
cuff technique during a week before measurements were recorded.
A Physiograph Desk Model and an Electro-Sphygmomanometer
(BIOSEB; Paris, France) were used. Five separate measurements
were made on conscious animals for systolic blood pressure
determinations.
Echocardiography examination
In vivo transthoracic echocardiography was performed using a
VEVO 770 ultrasound machine from Visualsonics equipped with
a 15-MHz imaging transducer in mice anesthetized with
isoflurane. Briefly, a two-dimensional short axis view of the left
ventricle was obtained at the level of the papillary muscle in order
to record M-mode tracings. Diastolic left ventricular dimension
(LVDED), systolic left ventricular dimension (LVSED) and cardiac
output were measured. Cardiac index was calculated by
normalizing the cardiac output to the animal body weight.
Vascular reactivity
Thoracic aorta was dissected and placed in modified Krebs-
Henseleit bicarbonate solution (KHS), final composition in
mmol/l: NaCl 118, KCl 4.75, NaHCO3 25, MgSO4 1.2, CaCl2
1.8, KH2PO4 1.18, and glucose 11. Aortic rings (1.5–2 mm in
length) were mounted on a wire myograph (Danish MyoTechnol-
ogy, Aarhus, Denmark) filled with KHS. Arterial segments
were stretched to a resting tension of 5 millinewtons and
allowed to equilibrate for 30 min. Endothelium-dependent
vasodilatation in response to acetylcholine (ACh, 1 nmol/l to
10 mmol/l) was studied in aortas with endothelium pre-contracted
with the thromboxaneA2 agonist (9,11-dideoxy-11a, 9a-
epoxymethanoprostaglandinF2a) U46619 at 80% of their maximal
response.
Concentration-response curves were assessed in the absence and
in the presence of the NO synthase (NOS) inhibitor N
v-nitro-L-
arginine-methyl ester (L-NAME; 300 mmol/l).
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paramagnetic resonance (EPR)
Aorta, liver, skeletal muscle and heart were dissected and
incubated for NO production for 30 min in Krebs–Hepes buffer
containing albumin, CaCl2 and L-Arginine. Sodium-diethyldithio-
carbamate (NaDETC) and FeSO4?7H2O were separately dis-
solved under argon gas bubbling in 10 mL volumes of ice-cold
Krebs–Hepes buffer. These were rapidly mixed to obtain a pale
yellow-brown opalescent colloid Fe(DETC)2 solution, which was
used immediately. The colloid Fe(DETC)2 solution was added to
vessels and incubated for 45 min at 37uC. Then, tissues were
immediately frozen in plastic tubes using liquid N2.N O
measurement was performed on a table-top x-band spectrometer
Miniscope (Magnettech, MS200; Berlin, Germany). Recordings
were made at 77 uK, using a Dewar flask. Instrument settings
were 10 mW of microwave power, 1 mT of amplitude modula-
tion, 100 kHz of modulation frequency, 150 s of sweep time and 3
scans [16]. Signals were quantified by measuring the total
amplitude, after correction of baseline as done previously [16].
Values are expressed in unit/mg weight of dried tissue.
Mitochondrial enzyme activities in muscles and liver
homogenates
Muscles and liver homogenateswere prepared as previously
described and activities of citrate synthase (CS), complex I, II, III
and IV were measured spectrophotometrically at 37uC via an
adaptation of the method described by Malgat et al. [17], and in
agreement with the Mitochondrial Diseases Group of the
Association Franc ¸aise de Myopathie. NADH ubiquinone reduc-
tase (complex I) was determined by monitoring the oxidation of
NADH at 340 nm. Succinate ubiquinone reductase (complex II)
was measured by following the reduction of 2,6-dichloropheno-
lindophenol at 600 nm. The assay of complex II is a function of
both succinate oxidation and electron transfer to ubiquinone.
Ubiquinone cytochrome c reductase (complex III) was determined
by monitoring the reduction of cytochrome c at 550 nm.
Cytochrome c oxidase (complex IV) activity was measured by
monitoring the oxidation of reduced cytochrome c at 550 nm. CS
activity was measured by monitoring the change in optical density
of 5,59-dithio-bis(2-nitrobenzoic acid) at 412 nm. Enzymatic
activities are expressed in nmol of product formed per min and
per mg of protein in homogenates. Protein concentrations were
determined by Lowry’s method.
ATP levels in liver homogenates
ATP concentration was determined in liver homogenates by a
colorimetric assay following the manufacturer-recommended
protocol (Abcam, Cambrigde, UK).
Data analysis
Data represented are means 6 SEM of n=10 animals.
Relaxation induced by ACh was expressed as a percentage of
the contraction. Graph-Pad Prism Software Version 5.0 (San
Diego, CA) was used to calculate nonlinear regression. For glucose
and insulin tolerance tests, areas under curves were analyzed in
each individual incremental glucose concentration curve in order
to evaluate the glycaemia reached during the whole assay period.
Differences between means were assessed by one-way analysis of
variance followed by Bonferroni’s test, except in vascular reactivity
experiments where a two-way analysis of variance was used to
compare concentration–response curves with agonists. Differences
were considered significant when P,0.05. StatView Software
package Version 5.0 (SAS Institute Inc, Cary, NC) was used for
statistical analysis.
Drugs and chemicals
PLC was kindly provided by Sigma-Tau (Pomezia, Italy). All the
chemicals were purchased from Sigma Chemical Co (St Louis,
MO, USA).
Results
Food intake and body and organ weights
As expected, after receiving the HF feeding during 9 weeks,
animals displayed higher values of body weight than those fed with
the standard food (data not shown).
Focusing on the PLC treatment period (i.e. next 4 weeks), it was
observed a greater body weight gain in vehicle-HF vs vehicle-ST
(Figure 1A, P,0.01 vs vehicle-ST) and PLC treatment completely
blunted this increase (Figure 1A, P,0.01 vs vehicle-HF). HF
groups displayed lower food intake compared to vehicle-ST group
(Figure 1B, P,0.01 vs vehicle-ST). However, the effect of PLC was
not due to changes in food intake between the HF groups
Figure 1. PLC treatment decreases high-fat (HF) diet-induced
body weight gain without changing the food intake in mice
with established diet-induced obesity (i.e. mice previously fed.
A: Body weight increases during PLC treatment period (from 9
th to 14
th
week). B: Daily food intake. Values are means and SEM (n=10).
##P,0.01,
###P,0.001 vs vehicle-ST, **P,0.01 vs vehicle-HF.
doi:10.1371/journal.pone.0034268.g001
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vehicle-HF and PLC-HF (Figure 1B).
The greater values of body weight found in animals fed with the
HF diet was accompanied by higher weight values of liver and fat
accumulated around different tissues: epididymal, abdominal,
mesenteric and subcutaneous fats (P,0.001 vs vehicle-ST,
Table 1). Interestingly, the increases of either liver (P,0.001) or
visceral fat weights (epididymal-P,0.001-, mesenteric-P,0.05-
and abdominal-P,0.01-) were lower than those of the vehicle-HF
group after PLC treatment (Table 1). In contrast, no changes
between weights of lean mass organs (i.e. heart, pancreas, spleen or
kidneys) were found between groups (Table 1).
Plasma free L-carnitine and acylcarnitine levels
To ensure that the effects observed during oral treatment of
PLC were effectively due to PLC itself but not to its metabolites,
we have measured plasmatic PLC and free L-carnitine. Interest-
ingly, animals receiving PLC treatment during four weeks showed
the highest plasmatic concentrations of both free-L-carnitine and
PLC (P,0.01 vs vehicle-ST and vehicle-HF and P,0.05 vs
vehicle-ST and vehicle-HF, respectively, Table 2). These results
provide evidence of intestinal absorption of PLC, although a
partial hydrolysis of this compound cannot be excluded.
Moreover, the observed effect of treatment can be accounted for
both PLC and L-carnitine.
Interestingly, untreated fatty animals displayed a lower
concentration of plasmatic long-chain acylcarnitines compared
to the vehicle-ST group (P,0.05 vs vehicle-ST) but not to PLC-
HF group.
Glucose tolerance and sensitivity to insulin
As shown in Table 2, HF diet induced a significant increase in
fasting glucose concentrations, insulin and subsequently HOMAIR
compared to vehicle-ST, demonstrating the presence of the insulin
resistance state. This insulin-resistance state was improved by PLC
treatment since the animals receiving this carnitine derivate
significantly reduced plasmatic insulin and HOMAIR (P,0.001 vs
vehicle-HF, Table 2) and fasting glucose was not significantly
different to vehicle-ST.
Such results were supported by those obtained in two functional
tests, the glucose and the insulin tolerance tests. The glucose
Table 1. PLC treatment decreases the weight values of liver and fat accumulated around different tissues (epididymal, abdominal,
mesenteric and subcutaneous fats) induced by the HF fed animals.
Vehicle-ST Vehicle-HF PLC-HF
Final body weight (g) 25.6 (0.68) 41.6 (1.57)
### 35.1 (1.06)
###**
Wet
weight (g)
% of body
weight
Wet
weight (g)
% of body
weight
Wet
weight (g)
% of body
weight
Heart 0.12 (0.01) 0.57 (0.02) 0.15 (0.01) 0.58 (0.02) 0.15 (0.01) 0.59 (0.04)
Lung 0.18 (0.01) 0.65 (0.03) 0.19 (0.01) 0.75 (0.06) 0.17 (0.01) 0.66 (0.03)
Spleen 0.16 (0.09) 0.64 (0.36) 0.12 (0.01) 0.29 (0.03) 0.21 (0.08) 0.37 (0.09)
Kidney 0.35 (0.01) 1.36 (0.02) 0.48 (0.02) 1.16 (0.04) 0.42 (0.01) 1.21 (0.04)
Pancreas 0.26 (0.05) 0.90 (0.03) 0.22 (0.02) 0.85 (0.07) 0.24 (0.03) 0.92 (0.12)
Liver 0.96 (0.03) 3.75 (0.10) 2.62 (0.43)
### 6.29 (1.36)
### 1.61 (0.14)
###*** 4.06 (0.56)
#***
Adipose tissue:
Epididimal 0.35 (0.05) 1.39 (0.21) 2.06 (0.14)
### 4.95 (0.33)
### 1.52 (0.09)
###** 4.34 (0.29)
###
Abdominal 0.17 (0.02) 0.66 (0.11) 0.95 (0.15)
### 2.30 (0.32)
### 0.74 (0.08)
###* 2.13 (0.22)
###
Mesenteric 0.17 (0.03) 0.66 (0.11) 0.73 (0.08)
### 1.76 (0.19)
### 0.40 (0.06)
#** 1.16 (0.10)
*
Subcutaneous 0.26 (0.05) 1.02 (0.20) 2.69 (0.26)
### 5.98 (0.63)
### 1.93 (0.19)
###** 5.50 (0.41)
###
Lean organ weights are not different between the three groups. Values are means and SEM (n=10).
###P,0.001 vs vehicle-ST,
*P,0.05,
**P,0.01 and
***P,0.001 vs vehicle-HF.
doi:10.1371/journal.pone.0034268.t001
Table 2. PLC exerts beneficial effects on different
biochemical plasma parameters evaluating the presence of
insulin resistance, the lipid profile and the free- and acyl-
carnitines plasma levels.
Vehicle-ST Vehicle-HF PLC-HF
Fasting glucose (mg/dL)110.40 (20.67) 218.10 (17.60)
## 168.50 (21.34)
Insulin (ng/mL) 0.72 (0.13) 2.37 (0.37)
### 1.15 (0.17)
###***
HOMAIR 5.28 (1.52) 31.28 (5.44)
### 14.83 (2.76)
###***
Triglycerides (mg/dl) 102.88 (11.85) 131.65 (24.03)
### 137.85 (14.10)
###
NEFA (mg/dL) 29.53 (2.43) 41.40 (1.95)
### 38.38 (1.18)
#
Cholesterol (mg/dl) 88.39 (5.50) 202.74 (16.03)
### 175.30 (11.71)
###**
HDL/LDL 13.92 (2.52) 4.36 (0.52)
## 4.60 (0.31)
##
Free LC (mmol/l) 24.17 (2.85) 23.00(1.55) 35.75 (1.00)
##**
PLC (mmol/l) 0.50 (0.10) 0.41 (0.03) 1.05 (0.30)
#*
LC-AC (mmol/l) 1.45 (0.20) 0.92 (0.05)
# 1.13 (0.10)
LC: L-carnitine; PLC: propionyl-l-carnitine; LC-AC: long-chain acylcarnitines.
Values are means and SEM (n=10).
#P,0.05,
##P,0.01,
###P,0.001 vs vehicle-ST,
*P,0.05,
**P,0.01 and
***P,0.001 vs vehicle-HF.
doi:10.1371/journal.pone.0034268.t002
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overload, animals fed with the HF diet developed post-load
hyperglycaemia compared to the vehicle-ST group throughout the
assay (P,0.001 vs vehicle-ST, Figure 2A). However, this glucose
overload led to a significant increase of glycaemia only in the
vehicle-HF (P,0.01 vs vehicle-ST, Figure 2B and C), whereas the
incremental glycaemia maintained during the test remained
similar in the vehicle-ST and the PLC-HF groups (Figure 2B
and C).
The intraperitoneal administration of insulin led to a decrease of
systemic glucose concentration in every experimental group
during the insulin tolerance test (Figure 2D). As expected, both
HF groups developed a blunted response of glucose concentrations
following insulin injection (P,0.001 vs vehicle-ST, Figure 2D and
E). Most importantly, such insulin-induced glycaemia decrease
resulted significantly less damaged in the PLC-HF group
compared to vehicle-HF (P,0.01 vs vehicle-HF, Figure 2F),
supporting the existence of an enhanced response to insulin after
PLC treatment.
Plasmatic lipid profile
A negative lipid profile was found in obese animals treated or
not with PLC compared to lean mice since they presented
enhanced plasmatic concentrations of NEFA (P,0.01 vs vehicle-
ST, Table 2), triglycerides, total cholesterol (P,0.001 vs vehicle-
ST, Table 2) and a lower HDL/LDL ratio (P,0.01 vs vehicle-ST,
Table 2). In HF-fed mice, PLC treatment did not modify the lipid
profile except the reduction of total cholesterol (P,0.01 vs vehicle-
HF) (Table 2).
Mitochondrial activity in muscle or liver homogenates
HF diet resulted in alterations in liver mitochondrial function
(Table 3). Activity of respiratory chain complexes I, II, III and IV
was significantly lower than in the lean control group (Table 3,
P,0.05). There was no significant difference in CS activity
between vehicle-HF and vehicle-ST expressed by mg of protein in
the homogenate (Table 3) or by per g wet liver. In addition
expression of CS in liver by western Blot analysis with actin as
reference was also similar in the two groups (data not shown)
suggesting that the HF diet-dependent decrease in activity of
complexes was not due to variation in mitochondrial mass. The
decrease activity of mitochondrial complexes was largely prevent-
ed by treatment with PLC. Moreover, PLC treatment led to an
increase in CS activity (Table 3, P,0.05 vs vehicle-HF) without
modification of the expression protein level (data not shown). In
contrast, we did not observe in the ‘‘red’’ muscle soleus any
differences between the three groups. However, in the white part
of the gastrocnemius muscle, activity of complex II was decreased
after HF diet feeding (P,0.05 vs vehicle-ST) that was completed
abolished upon PLC treatment.
Figure 2. PLC restores the impaired responses to glucose overload and insulin administration induced by high-fat (HF) fed animals.
A, B and C: Intraperitoneal glucose tolerance test performed in overnight fasted animals. A: Plasma glucose concentrations at baseline and at 30, 60,
90 and 120 minutes after glucose overload (2 mg/kg). B: Incremental glucose concentrations at 30, 60, 90 and 120 minutes after glucose overload. C:
Area under curves describing the increase of glycaemia from 0 to 120 minutes after the glucose overload. D, E and F: Insulin sensitivity test. D. Plasma
glucose concentrations at baseline and at 30, 60, 90 and 120 after insulin administration (0.8 U/kg body weight). E: Decrease of glycaemia suffered at
30, 60, 90 and 120 after insulin injection. F Area under curves describing the decrease of glycaemia from 0 to 120 minutes after the insulin
administration. Values are means and SEM (n=10).
##P,0.01,
###P,0.001 vs vehicle-ST, *P,0.05 vs vehicle-HF.
doi:10.1371/journal.pone.0034268.g002
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To better illustrate PLC effects on hepatic energy metabolism in
HF-fed animals, ATP concentration was measured in liver
homogenates. According to that observed in mitochondrial
activity, HF-diet induced a decrease in ATP hepatic concentration
(P,0.05 vs. vehicle-ST). The ATP concentrations were 0.9660.17
and 0.5160.09 in control and HF-diet animals, respectively.
Interestingly, PLC treatment was accompanied by the restoration
of ATP levels in the liver of obese animals (0.9860.18, P,0.05 vs.
vehicle-HF).
Tissue NO production
EPR measurement of NO showed that HF diet induced a
significant decrease of NO production in the skeletal muscle and
the aorta (Figure 3A and B, P,0.01 and P,0.05 vs vehicle-ST,
respectively) but not in the heart (Figure 3C). Interestingly, PLC
treatment greatly enhanced its production in these three tissues
from mice receiving HF diet (Figure 3A, B and C, P,0.001 vs
vehicle-HF). In the hepatic tissue a non significant decrease in NO
was found in PLC-treated or not-treated HF animals in relation to
the vehicle-ST group (Figure 3D).
Cardiac function and systolic blood pressure
The effect of PLC on the structure and function of the left
ventricle was assessed by echocardiography (Figure 4). We found
that HF diet did not alter both LVESD and LVEDD (Figure 4A
and 4B). PLC treatment slightly increased LVEDD but not
LVESD in HF animals compared to vehicle-HF (P,0.01). Of note
is that ejection fraction values were not different in the three
groups (Figure 4C). Although HF diet did not significantly
decrease cardiac output compared to vehicle-ST (Figure 4D),
these mice exhibited decreased cardiac index when the values
were normalized to the body weight (Figure 4E, P,0.001 vs
vehicle-ST). Interestingly, PLC treatment significantly increased
both cardiac output and cardiac index in animals receiving HF
diet (Figure 4E, P,0.05). Finally, the systolic blood pressure did
not change with diets or PLC treatment (Figure 4F).
Aortic endothelial function
Endothelial dysfunction, which is a key early factor in the
development of atherosclerosis and a predictor of cardiovascular
events, has been found in patients with obesity and metabolic
syndrome. Thus, we evaluated the endothelial function in aorta
from vehicle and HF animals and evaluated the potential
protective effect of PLC. As shown in Figure 5, aortic rings from
mice receiving HF diet displayed reduced endothelium-dependent
relaxation to ACh compared to aortic rings from vehicle-ST
(P,0.01). PLC significantly corrected the impairment in endothe-
lium-dependent relaxation in aortas from mice receiving HF diet
(P,0.01 vs vehicle-HF). In the presence of the non-selective NO
synthase inhibitor, L-NAME, the endothelium-dependent relaxa-
tion to ACh was completely abolished in aortic rings from the 3
groups of animals.
Discussion
The present study shows that PLC was able to lower the body
weight gain in an experimental model of DIO, once the obesity is
established. PLC improved the insulin-resistant state induced by
HF feeding, likely through the restoration of a normal hepatic
metabolism and lowering of tissue accumulation of toxic
incompletely metabolized fatty acids. Accordingly, the improve-
ment of the insulin sensitivity was accompanied by an enhanced
NO production in skeletal muscle, heart and aorta. Additionally,
PLC lowered the cardiovascular risk observed in HF-fed animals
inasmuch it restored cardiac and endothelial functions, decreased
visceral obesity and lowered the circulating total cholesterol.
The most important finding of the present study was the
improvement of the obesity-related insulin resistance state by the
PLC treatment, as shown by correction of insulinemia, HOMAIR
and insulin tolerance test data. We have previously found similar
systemic effects in obese Zucker rats [11] and DIO mice
(unpublished data) when PLC treatment was started prior to
HF-diet. Here, we extent the beneficial action of PLC treatment
on the insulin-resistant state even when obesity had already been
well established.
PLC-treated animals displayed a decrease accumulation of
ectopic visceral fat mass. This reduction of body weight and
visceral adiposity was not related to a reduced food intake
suggesting the existence of other mechanisms probably targeting
the adipose tissue. In this sense, it has been described that the
treatment of murine preadipocyte 3T3-L1 with L-carnitine
reduced the content of triglycerides and total lipids after
differentiation [18]. Furthermore, in mature adipocytes, L-
carnitine induced the expression of genes involved in b-oxidation
and lipolysis and suppression of genes involved in adipogenesis
[19]. Finally, the direct effect of L-carnitine on the b-oxidation
occurred in adipose tissue was recently confirmed in human
preadipocytes [20]. This L-carnitine lipolytic action on adipose
tissue could explain that, decreasing visceral fat accumulation,
PLC treatment produced no changes in plasma levels of free fatty
acids.
Ectopic visceral adiposity is the main source of inflammatory
cytokines responsible for the development of obesity-induced
insulin resistance [21]. Then, regardless of the mechanisms
Table 3. PLC treatment improves activity of mitochondrial
respiratory chain complexes.
Complex Vehicle-ST Vehicle-HF PLC-HF P value
Liver
CS 355.25627.71 365.25610.83 480.52641.11* ,0.05
I 147.25623.43 107.2618.32
# 126.20623.91 ,0.05
II 228.72645.70 174.2167.13
# 222.21641.02 ,0.05
III 70.7067.71 38.0362.41
# 50.11617.51 ,0.05
IV 239.23638.22 190.72618.51
# 233.00655.11 ,0.05
Gastrocnemius muscle
CS 440.82683.61 380.11665.95 485.06651.80 ns
I 90.71623.82 96.33648.65 93.95660.71 ns
II 59.13611.01 44.71611.91
# 71.22616.23 ,0.05
III 269.24637.60 290.85633.51 352.12676.55 ns
IV 354.536194.40 281.516179.13 487.156307.10 ns
Soleus muscle
CS 925.556100.41 935.90654.51 951.13670.50 ns
I 487.41695.82 470.016130.84 393.95658.60 ns
II 213.74655.72 184.11627.40 170.91642.10 ns
III 225.50696.41 144.25683.65 169.54657.21 ns
IV 620.206213.23 654.916340.05 647.11660.45 ns
CS: citrate synthase. Enzymatic activities are expressed in nmol of product
formed per min and per mg of protein. Values are means and SEM (n=10).
#P,0.05 vs vehicle-ST,
*P,0.05 vs vehicle-HF.
doi:10.1371/journal.pone.0034268.t003
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e34268responsible for the effects of PLC treatment on visceral fat mass, its
reduction may lead to the improvement of the insulin-resistant
state in DIO animals. Such results are in accordance to those
reported by Amin et al. [22] in which L-carnitine given in HF-
induced obese rats induced a decreased of HOMAIR accompanied
by the loss of body weight. However, L-carnitine itself has also
demonstrated some beneficial effects in insulin resistance without
necessarily decreasing body weight [23], leading to the opening of
extra hypothesis explaining the effects of L-carnitine and PLC on
insulin resistance.
The sequence of events leading to the development of insulin
resistance after starting a HF diet is still incompletely understood.
Because of the central role of the liver in the whole-body energy
homeostasis, liver insulin sensitivity and its potential relationship
with mitochondrial oxidative phosphorylation appear to be crucial
in the development of insulin resistance. Growing evidences
suggest that liver rapidly respond to HF diet by metabolic and
inflammatory responses that may be involved in the onset of
insulin resistance [24,25]. Alterations in the oxidative phosphor-
ylation pathways in liver mitochondria have been reported in
various rodent model of insulin resistance induced by HF diet with
some conflicting results concerning respiratory chain complex
activities [26,27]. Here, we report decreased activities affecting all
the complexes. Moreover, the reduced activities of complexes were
not accompanied by a decrease of CS activity, supporting an
intrinsic mitochondrial dysfunction rather than a lower mitochon-
drial number. This change in respiratory chain function was
associated with a significant reduction of ATP concentration in
liver homogenates indicating either a much lower ATP synthesis
or a loss of the mitochondrial capacity to meet an increased
energetic demand under conditions of metabolic stress such as
high fat diet. Whatever the exact explanation, it is interesting to
note that oral treatment with PLC led to a normalization of
hepatic ATP levels and that is associated with complete correction
of respiratory chain enzyme activities and with an increase in CS
activity. This high citrate synthase activity might be secondary to
an enhancement of specific activity since we didn’t observe change
in the level of protein expression. The mechanism for this is still
unknown but recently a covalent modification of CS by
phosphorylation/dephosphorylation was hypothesized to explain
change in CS specific activity in response to insulin in cultured
skeletal muscle cells [28]. Remarkably, the increased CS activity
and the correction of liver mitochondrial function are associated
with an improvement in peripheral insulin sensitivity as assessed
by the insulin tolerance test.
Moreover, also supporting the hypothesis of an improved
insulin signaling pathway secondary to PLC administration, we
may well take into account the results related to NO production.
Several studies have reported that insulin, in addition to its
metabolic modulation, directly activates vascular endothelial and
myocardial protein kinase B–endothelial NO synthase (Akt–
eNOS) signaling, leading to enhance endogenous NO production.
Accordingly, the deterioration of this insulin-induced NO release
is frequently found in the insulin resistance state [29] and of
particular interest is the increase of muscle NO availability
reported in this study with PLC treatment.
Figure 3. PLC increased the nitric oxide (NO) release in heart, skeletal muscle and aorta. Measurement of in situ NO production by
electron paramagnetic resonance in skeletal muscle (A), aorta (B), heart (C) and liver (D). Values are means and SEM (n=10).
##P,0.01,
#P,0.05 vs
vehicle-ST, ***P,0.001, *P,0.05 vs vehicle-HF.
doi:10.1371/journal.pone.0034268.g003
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34268The improvement of insulin sensitivity observed in treated
animal with PLC could be interpreted as an indirect consequence
of ameliorated liver function. Recent study demonstrated that liver
by the way of the production of secretory proteins termed
hepatokines may modulate the sensitivity of peripheral tissues to
insulin [30]. It is also possible that PLC treatment directly exerts its
beneficial effects on muscle since whole body insulin resistance
depends to a great extent on muscle insulin resistance. Recently,
Koves et al [31] have provided evidence that insulin sensitivity is
compromised when the b-oxidation of fatty acids exceeds the
capacity of the tricarboxylic acid cycle, leading to incomplete fatty
acid oxidation. Here, the lower level of circulating acylcarnitines in
animal fed with a HF diet may be a marker of the impaired
capacity of mitochondria to export acylcarnitines resulting of the
incomplete NEFA oxidation [32,33]. In contrast, PLC treated
animals showed an improved capacity for carrying out the cell
these potentially toxic lipid intermediates and it is tempting to
attribute the result to both the anaplerotic and the carnitine effects
of the molecule. Further studies will be required to evaluate these
two mutually non exclusive hypotheses.
The deterioration of the insulin-induced NO release is included
between the major causes of endothelial dysfunction and
cardiovascular disease related to obesity and insulin resistance
[34]. Accordingly to this observation and to other previous reports,
in the present work HF-feeding led to the development of
endothelial dysfunction [35,36]. As expected considering the
enhanced NO release observed in the arteries from PLC-treated
animals, PLC ameliorated such deteriorated arterial function.
Obesity is also a known risk factor for developing heart failure
and it has been mainly related to the development of left
ventricular hypertrophy and diastolic dysfunction [37]. In the
present study, DIO was not related to cardiac hypertrophy.
Moreover, the DIO animals did not develop hypertension,
condition that is frequently necessary for the development of the
obesity-induced cardiac hypertrophy. In contrast, an altered
cardiac function related to obesity and insulin resistance could
Figure 4. PLC improves cardiac function. A: Left ventricular systolic end diameter. B: Left ventricular diastolic end diameter. C: Ejection fraction.
D: Cardiac output. E: Cardiac index (cardiac output normalized to the animal body weight). F: Systolic blood pressure. Values are means and SEM
(n=10).
###P,0.001 vs vehicle-ST, *P,0.05, **P,0.01 vs vehicle-HF.
doi:10.1371/journal.pone.0034268.g004
Figure 5. PLC improves high-fat (HF) diet-induced endothelial
dysfunction. Concentration-response curves to acetylcholine (ACh,
1 nmol/l to 10 mmol/l) in the presence and in the absence of the nitric
oxide synthase inhibitor N
v-nitro-L-arginine-methyl ester (L-NAME
300 mmol/l). Values are means and SEM (n=10).
XXXP,0.001 vs ACh
in the absence of L-NAME,
##P,0.01 vs vehicle-ST, **P,0.01,
***P,0.001 vs vehicle-HF.
doi:10.1371/journal.pone.0034268.g005
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e34268be pointed out as a decreased cardiac index was found in fatty
animals. It is hardly to find previous reports describing such effect
in the DIO models since different parameters to this cardiac index
were used to evaluate the cardiac functionality (i.e. shortening
fraction, LVEDD or cardiac output) [38–40]. However, the
cardiac output is linearly related to the body weight, thus
calculating the cardiac index allows a further accurate comparison
between individuals with differing body weights. In fact, it has
even been described the presence of enhanced cardiac output in
obese individuals, whereas the cardiac index was lower in obese
than in non-obese patients [41]. Interestingly, oral treatment with
PLC led to an improvement of both the cardiac output and the
cardiac index of DIO animals. The beneficial effects of PLC in the
cardiac functionality have been deeply covered by the literature of
the last decades, especially when they were evaluated in diabetic
hearts [42]. Although the reduced toxic effects of incomplete b-
oxidation byproducts or the enhanced NO production observed in
PLC-treated animals may well be pointed out as responsible for
such effects in myocardial function, the cardioprotective action of
PLC in ischemic heart has also been traditionally related to an
improvement of ATP production by enhancing the glucose
oxidation [43]. It has been suggested that the mitochondrial
export of acetylcarnitine lowers concentration of acetylCoA, which
in turn favours increased pyruvate dehydrogenase activity and
higher rates of glucose oxidation [43]. As a result, future studies
should be driven to test the relation between pyruvate dehydro-
genase activity and the beneficial effects of PLC in insulin
resistance.
In conclusion, the present study provides evidence that PLC
corrected the metabolic and cardiovascular alterations induced by
HF feeding. Improved glucose tolerance and insulin sensitivity
may participate to these beneficial effects of PLC probably via
correction of the hepatic mitochondrial function and diminution of
the excessive accumulation of lipid metabolism intermediates.
Thus, PLC may be of potential use to treat metabolic and
cardiovascular alterations associated with obesity.
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